Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism

Proceedings of the National Academy of Sciences of the United States of America
Daniel C ChanPaul A Bunn

Abstract

All small cell (SCLCs) and many non-small cell lung cancers (NSCLCs) have neuroendocrine features including production of neuropeptides and cell surface receptors creating autocrine and paracrine growth loops. Neuropeptides bind to a family of 7-transmembrane receptors and activate heterotrimeric G proteins consisting of G(alphaq) and G(alpha12,13). Substance P derivatives (SPDs) induced apoptosis and inhibited growth of lung cancer cells by discoordinately inhibiting G(alphaq) and stimulating G(alpha12,13). However, these SPDs had low potency and short half-lives. In this report we show that a bradykinin antagonist dimer, CU201, inhibited the growth of SCLC and NSCLC cell lines with or without multidrug-resistant proteins and was 10-fold more potent with a longer plasma half-life than SPDs. Bradykinin agonists in either monomeric or dimeric form and monomeric bradykinin antagonist have no effect on lung cancer cell growth. The dimeric linking moiety of the two molecules was created, requiring a sufficient number of carbon chains to provide critical spacing between the two antagonists. CU201 inhibited intracellular Ca2+ release in response to bradykinin, indicating blockage of the G(alphaq) signal, and stimulated c-Jun kinases,...Continue Reading

References

Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P A BunnE Braunschweiger
Jun 1, 1988·British Journal of Cancer·J CarmichaelJ D Minna
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·D N CarneyJ D Minna
Mar 30, 1994·Biochemical and Biophysical Research Communications·J G Reeve, N M Bleehen
Jan 6, 1995·The Journal of Biological Chemistry·R Taussig, A G Gilman
Jun 1, 1996·Immunopharmacology·L Gera, J M Stewart
Jun 1, 1996·Immunopharmacology·L GeraJ S Zuzack
Dec 6, 1996·The Journal of Biological Chemistry·R MaggioG U Corsini
Jan 5, 1999·Science·R KunerH C Kornau
Nov 5, 1999·Pulmonary Pharmacology & Therapeutics·J M SiegfriedS P Shriver
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun
Oct 13, 2001·Cancer·C G Varricchio, J Stevens
Nov 10, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·D C ChanP A Bunn

❮ Previous
Next ❯

Citations

Apr 12, 1978·Biochimica Et Biophysica Acta·N KrishnanG Krishna
May 10, 2005·Peptides·John M StewartLaimute Taraseviciene-Stewart
Dec 20, 2002·International Immunopharmacology·John M StewartLajos Gera
Oct 2, 2004·Nature Reviews. Drug Discovery·François Marceau, Domenico Regoli
Dec 10, 2002·Annual Review of Medicine·Yoshitaka SekidoJohn D Minna
Aug 19, 2005·American Journal of Respiratory Cell and Molecular Biology·York E Miller
Aug 21, 2008·Biological Chemistry·Jessica CheeKanti D Bhoola
Feb 22, 2012·Expert Opinion on Therapeutic Targets·Carlos D FigueroaKanti D Bhoola
Oct 26, 2012·Expert Opinion on Drug Discovery·Eric T WhalleyKanti D Bhoola
Mar 23, 2010·Cancer Genetics and Cytogenetics·Muradiye NacakA Sükrü Aynacioğlu
Jan 5, 2005·Peptides·Ecio Alves NascimentoDurval Rosa Borges
Aug 13, 2011·Peptides·Patricia Dias FernandesPierre Sirois
Dec 9, 2004·Expert Opinion on Therapeutic Targets·Heather L HandlRobert J Gillies
Apr 2, 2003·Expert Opinion on Therapeutic Targets·John Howl, Sarah J Payne
Dec 18, 2013·Cancer Letters·Patrícia L N da CostaRoger Chammas
Mar 25, 2006·Angewandte Chemie·Laura L KiesslingLaura E Strong
Oct 1, 2009·Physiological Reviews·Carmen ClappGonzalo Martínez De La Escalera
Feb 1, 2006·Signal Transduction·Sylvia MuellerSiegmund Reissmann
Jun 5, 2003·Melanoma Research·William A RobinsonR Peter Nelson
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seong Il SeoDaqing Wu
Feb 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marius GrzelinskiAchim Aigner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.